Can scans predict muscle loss from popular diabetes drugs?
NCT ID NCT07156331
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will follow 20 adults with type 2 diabetes who are starting on semaglutide or tirzepatide. Researchers will use PET/CT scans and physical tests to track changes in muscle mass, strength, and bone health over one year. The goal is to find early warning signs of muscle or bone loss so doctors can take steps to prevent harm.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide or tirzepatide
What this could lead to
If successful, this could help doctors predict who is at risk of muscle or bone loss from these diabetes drugs, leading to better monitoring and preventive care.
What could go wrong
This is a very small, early exploratory study with only 20 people, so results may not apply to everyone. It is designed to gather information, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••